论文部分内容阅读
目的探讨重组人血管内皮抑制素(恩度)联合顺铂治疗肺癌并恶性胸腔积液的临床疗效。方法选择2014年7月—2015年10月云南省肿瘤医院接收的40例晚期肺癌患者40例,按照随机数字表法分为对照组和观察组,各20例。对照组患者均采用恩度单药胸腔灌注给药,观察组患者在恩度单药局部应用的基础上给予顺铂局部灌注化疗。观察两组患者治疗后临床疗效及不良反应发生情况。结果观察组患者总有效率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论恩度联合顺铂治疗肺癌并恶性胸腔积液的临床疗效显著,不增加化疗的毒副作用,安全性好。
Objective To investigate the clinical efficacy of recombinant human endostatin (Endostar) combined with cisplatin in the treatment of lung cancer with malignant pleural effusion. Methods Forty cases of 40 patients with advanced lung cancer received from Yunnan Cancer Hospital from July 2014 to October 2015 were randomly divided into control group and observation group according to random number table. Patients in the control group were given single-agent pleural perfusion administration, and patients in the observation group were given cisplatin locally perfusion chemotherapy on the basis of local application of single-drug Endue. The clinical efficacy and adverse reactions of the two groups were observed after treatment. Results The total effective rate of observation group was higher than that of control group, the incidence of adverse reactions was lower than that of control group, the difference was statistically significant (P <0.05). Conclusions Endood combined with cisplatin in the treatment of lung cancer and malignant pleural effusion has a significant clinical effect, does not increase the side effects of chemotherapy, good safety.